2019
DOI: 10.1002/epi4.12339
|View full text |Cite
|
Sign up to set email alerts
|

De novo variants in SETD1B cause intellectual disability, autism spectrum disorder, and epilepsy with myoclonic absences

Abstract: Epilepsy with myoclonic absences is a specific seizure type characterized by bilateral rhythmic clonic jerks with impairment of consciousness. Here, we report an individual with epilepsy with myoclonic absences, mild intellectual disabilities, language disorder, and autism spectrum disorder. His interictal electroencephalogram revealed a spike‐and‐slow wave complex dominant in the frontal area. His ictal polygraphic and video‐electroencephalogram showed a characteristic diffuse synchronous 3‐Hz spike‐and‐wave … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
26
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 31 publications
(29 citation statements)
references
References 22 publications
1
26
1
Order By: Relevance
“…We report on the molecular and phenotypic spectrum of 36 individuals with sequence variants in SETD1B, representing the largest cohort reported to date. Previous work suggested a possible gain-of-function effect of pathogenic variants in SETD1B [14]; however, further reports [8,12,13,[15][16][17][18][19], including this work, point toward a loss-of-function mechanism. Clinical features of our cohort compared to previously reported individuals with a (likely) pathogenic SETD1B variant [8,[12][13][14][15] are provided in Table 2.…”
Section: Discussioncontrasting
confidence: 48%
See 2 more Smart Citations
“…We report on the molecular and phenotypic spectrum of 36 individuals with sequence variants in SETD1B, representing the largest cohort reported to date. Previous work suggested a possible gain-of-function effect of pathogenic variants in SETD1B [14]; however, further reports [8,12,13,[15][16][17][18][19], including this work, point toward a loss-of-function mechanism. Clinical features of our cohort compared to previously reported individuals with a (likely) pathogenic SETD1B variant [8,[12][13][14][15] are provided in Table 2.…”
Section: Discussioncontrasting
confidence: 48%
“…This indicates that SETD1B dysfunction severely impacts physiological neurodevelopment even in the absence of epilepsy, suggesting the condition is a developmental encephalopathy, with or without epilepsy. Previously alterations of SETD1B were mainly associated with myoclonic absences [13] and predominantly refractory epilepsy. Although myoclonic absence seizures were often observed in our cohort-confirming this association-other seizure types were regularly encountered at onset, including focal or generalized tonic-clonic seizures.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This work reports on the molecular and phenotypic spectrum of 36 individuals with sequence variants in SETD1B , representing the largest cohort reported to date. Previous work suggested a possible gain-of-function effect of pathogenic variants in SETD1B 14 , however, further reports 8,12,13, 15–19 including this work, point towards a loss-of-function mechanism. Clinical features of our cohort compared to the eleven previously reported individuals with a (likely) pathogenic SETD1B variant 8,1215 is provided in Table 2.…”
Section: Discussionmentioning
confidence: 43%
“…This indicates that SETD1B dysfunction severely impacts physiological neurodevelopment even in the absence of epileptic activity, suggesting the condition is a developmental encephalopathy, with or without epilepsy. Previous work emphasized that alterations of SETD1B were mainly associated with myoclonic absences 13 and predominantly refractory epilepsy. Although myoclonic absence seizures were often observed in our cohort – confirming this association – also other seizure types were regularly encountered at onset, including focal or generalized tonic-clonic seizures.…”
Section: Discussionmentioning
confidence: 99%